Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT02775461 |
| Other study ID # |
GCO 13-0222 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
March 1, 2013 |
| Est. completion date |
November 2033 |
Study information
| Verified date |
January 2024 |
| Source |
Icahn School of Medicine at Mount Sinai |
| Contact |
Arielle Labiner |
| Phone |
212-241-2244 |
| Email |
Arielle.labiner[@]mssm.edu |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The purpose of this study is to establish a registry of patients with pancreatic diseases.
Patients included in the registry may include those with: pancreatic cancer, precancerous
lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the
pancreas, and patients at high-risk of pancreatic cancer such as those with a family history
of pancreatic cancer or with a family history of a syndrome known to be associated with
pancreatic cancer. Pancreatic cancer is the fourth leading cause of death from cancer in the
United States. However, little is known about the development of pancreatic cancer and
pancreatic diseases in individuals with the above conditions. Knowledge of how family
history, environmental exposures, and inflammatory lesion of the pancreas contribute to the
development of pancreatic cancer and pancreatic diseases is essential.
You may qualify to take part in this research study because you have inflammation in the
pancreas, a pancreatic cyst, pre-cancerous lesions of the pancreas, pancreatic cancer, a
family history of pancreatic cancer, or a family history of a syndrome known to be associated
with pancreatic cancer.
We will also be collecting a blood sample from all participants for DNA isolation. Sometimes
we are born with genes or DNA that give us an increased or decreased chance of developing an
illness later in life. Genetic material will be isolated from your blood for further study.
You may also choose to provide additional blood samples for serum and plasma extraction.
Serum and plasma are components of the blood which can be used to measure indicators of
disease in the blood, called biomarkers,for pancreatic diseases. Clinical data and biological
specimens contained in this study may be used for a wide variety of future related studies to
the cause, diagnosis, outcome and treatment of pancreatic cancer.
Funds for conducting this research are provided by Mount Sinai.
Description:
The overall purpose of this research project is to establish a registry of patients with
pancreatic diseases. Patients included in the registry may include those with: pancreatic
cancer, precancerous lesions of the pancreas such as intraductal papillary mucinous neoplasms
(IPMNs) and cystic lesions, inflammatory lesions and inflammation of the pancreas, and
patients at high-risk of pancreatic cancer such as those with a family history of pancreatic
cancer or with a family history of a syndrome known to be associated with pancreatic cancer.
The data contained in this registry will be used to conduct research related to the risk of
pancreatic cancer and pancreatic diseases. As this is a registry protocol, no specific
hypotheses are to be tested.
Specific Aims:
1. Establish and maintain a registry of individuals and their family members who have
pancreatic diseases and may be at increased risk of developing pancreatic cancer over
normal population risk.
2. Collect data and review existing data on personal and family histories, demographics,
risk factors, and health behaviors.
3. Use the data in the registry to conduct studies related to disease risk, prevention, and
prognosis of pancreatic cancer and other pancreatic diseases.
Pancreatic cancer is the fourth leading cause of death from malignancy in the United States.
With near equivalent incidence and mortality, cure can only be achieved with surgical
resection of an early stage lesion. Premalignant disease stages, such as IPMN, may be
detected with noninvasive and minimally invasive techniques, providing an opportunity for
screening and surveillance of at-risk populations.
Knowledge of the etiology of pancreatic cancer is incomplete. Approximately 10% of pancreatic
ductal adenocarcinoma (PDAC) has a hereditary component, and screening this population has
the potential to have an impact on disease mortality. Certain patient populations, such as
those with hereditary pancreatitis, Peutz-Jeghers syndrome, familial atypical multiple mole
melanoma (FAMMM syndrome), Lynch syndrome, and the breast ovarian cancer syndrome (BRCA1 and
BRCA2 mutations) are at the highest risk of PDAC. BRCA2 mutations are the most commonly
identified germline mutations in families with PDAC. Even a family history of PDAC without
the above described syndromes has been shown to increase risk, suggesting a unique familial
pancreatic cancer syndrome which may be related to the partner and localizer of BRCA2 (PALB2)
gene or other PDAC susceptibility genes. Environmental risk factors, such as cigarette
smoking, diabetes, obesity and dietary risk factors have been implicated in the development
of PDAC.
A sequential model of acquisition of somatic mutations via a Pancreatic Intraepithelial
Neoplasia (PanIN) has been proposed for the development of PDAC and subsequent metastases.
However, others have proposed that the metastatic process may be initiated earlier in the
disease process during the pre-malignant cyst or PanIN phase. This may in part account for
the fact that the overwhelming majority of patients diagnosed with PDAC are diagnosed when
the lesion is already metastatic.
Several groups have instituted PDAC screening for individuals at high-risk of PDAC. These
groups have demonstrated the feasibility of detection of PDAC and pre-malignant lesions in
certain high-risk individuals. Given the large gaps in knowledge, recruitment of patients
with preneoplastic pancreatic diseases to registries is essential in the development of
effective PDAC screening and prevention programs.
As an increasing number of patients undergo cross-sectional imaging with the abdomen with cat
scan (CT) and magnetic resonance imaging (MRI), an increasing number of patients are found to
have pancreatic disease and pancreatic cysts. While there is an increased risk of pancreatic
cancer with these lesions, the studies to date are small and retrospective.
